Outlook Therapeutics, Inc.
OTLK
NASDAQ·Healthcare·Biotechnology·Mkt cap $124.6M
$0.67
▲ +2.70%
P/E
-1.26
Mkt Cap
$124.6M
52-Wk Range
$0.16–$2.54
52-Week Range
$0.16 - $2.54
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 29.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
No bull reasons captured for this rating yet.
Bear Case
1 risk
- Low volatility (beta 0.8).
Growth
Stable outlook
Value
Deep value opportunity - significant discount to sector peers
Momentum
Weak
-7.7% over 3m
Quality
Excellent
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying OTLK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
AUG 13, 2026
Reported EPS of -$0.14 vs -$0.08 consensus (-75.0% surprise). Revenue of $9.0K vs $966.7K expected (-99.1%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-75.0%
Revenue trend · last 2Q
—
-99%
Q1 26
Q3 26
-$1.2M
$9.0K
Margins · last 2Q
Gross
-88.9%
Profit
-225766.7%
Wall Street consensus
2 analysts · 50% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
50%
Hold
50%
Sell
0%
Median Price Target
—
Latest: BTIG · Jul 27, 2026
vs Industry
How OTLK stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.